Why rubber closure extraction studies are critical:

Rubber closures—such as stoppers and septa—are commonly used in vials, ampoules, and injectable products stored in stability chambers. These elastomeric components can release extractables under heat, humidity, or solvent exposure, which may become leachables in the drug product. Performing extraction studies helps identify the profile of compounds that may migrate over time, preventing unforeseen safety risks, contamination, or regulatory hurdles.

Risks of not performing rubber closure extractables testing:

Without such studies:

• Undetected leachables may react with the drug product or alter its stability
• Subvisible particles or color changes may appear during storage
• Regulatory submissions may be flagged for incomplete container-closure evaluation
• Unexpected impurities or toxic substances may breach ICH limits

Extractables testing is a preventative tool to ensure long-term integrity of both product and packaging.

Regulatory and Technical Context:

ICH and WHO guidance on closure system testing:

ICH Q1A(R2), Q3B, and WHO TRS 1010 stress the importance of compatibility between the product and its container-closure system. For rubber materials, extractable and leachable assessments are required to confirm that no unsafe substances migrate into the product over time. CTD Module 3.2.P.2 and 3.2.P.7 must include extraction study summaries, test results, and toxicological risk assessments as part of the packaging system justification.

Inspection expectations for elastomeric packaging systems:

Regulators may request:

• Chemical characterization of rubber stoppers used in stability studies
• Evidence that extractables do not compromise drug quality
• Validated methods used to detect and quantify potential leachables

Inadequate closure evaluation could delay approvals or result in post-approval queries during lifecycle changes.

Best Practices and Implementation:

Design comprehensive extractables studies under worst-case conditions:

Use aggressive solvents (e.g., water, ethanol, hexane, 0.1N HCl) to extract potential compounds from the rubber material. Simulate worst-case storage by:

• Testing at 40°C or higher for defined time intervals
• Agitating samples to enhance contact
• Using actual closures from commercial lots

Analyze extract solutions via GC-MS, LC-MS, and ICP-MS to detect volatile, semi-volatile, and inorganic extractables.

Integrate extractables data into your leachables assessment:

Match the extractables profile with leachables observed in actual stability samples. Monitor:

• Changes in product color, clarity, or odor
• Emerging peaks in impurity chromatograms
• Toxicological thresholds based on permitted daily exposures (PDE)

Establish specifications or action limits for any identified leachables that may appear in the drug product over time.

Include extraction study documentation in regulatory filings:

Ensure submissions include:

• Justification for choice of rubber closure
• Summary tables of extractables by solvent and condition
• Risk assessment aligned with ICH M7 and USP / guidance

Demonstrating full awareness of rubber interaction risks enhances regulatory confidence in your packaging system design.

Performing extraction studies for rubber closures strengthens your stability program by proactively addressing potential leachable threats—ensuring your product remains safe, stable, and compliant throughout its shelf life.